Predict your next investment

Venture Capital
blueredpartners.com

See what CB Insights has to offer

Investments

9

Funds

1

About BlueRed Partners

BlueRed Partners is a Venture Capital fund investing in Israeli Technologies with a "go to market" in Asia.

BlueRed Partners Headquarter Location

Singapore

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest BlueRed Partners News

RenalSense raises $14M Series A Funding to Bolster Global Commercialization and Expand its Product Line

Nov 22, 2021

11/22/2021 | 09:01am EST Message : *Required fields JERUSALEM, Nov. 22, 2021 /PRNewswire/ --  RenalSense ™, a leader in real-time renal diagnostics, today announced it has secured $14M to bolster the global commercialization of its current product, the Clarity RMS, expand clinical validation to additional clinical settings, and advance the release of its next generation products based on its sensor platform. The Series A round was led by BlueRed Partners Fund (Singapore) and includes several large healthcare-focused family offices as well as existing shareholders. The Clarity RMS, RenalSense's first commercially available product, is a critical care monitoring system that has been clinically proven to facilitate early detection of changes in renal function and Acute Kidney Injury (AKI) risk, as well as treatment monitoring. It has FDA clearance as well as CE-certification and is installed in tens of general and cardiovascular operating rooms and intensive care units (ICU's) as well as transplant and COVID-19 units in leading medical centers in the US, Europe and Israel. Future generation sensor-based products will aim to provide additional diagnostic data about renal as well as other vital organ function, and to be implemented beyond the critical care setting. In addition to existing distribution partners Fresenius Medical Care (Europe), Medline (North America), and Gloryway  (China), over the last year RenalSense has expanded its global marketing network with new distributors in eastern Europe, Israel, and most recently in Taiwan, with PAHSCO . "RenalSense is a front-runner in digitalizing real-time renal monitoring, providing intensivists with a key indicator of vital organ function they have not had access to before," commented Yishai Klein, Managing Partner and Co-Founder of BlueRed Partners. "With increasing adoption by leading medical centers in the US and Europe, we look forward to supporting the company's growth as it extends its reach to Asia and expands its product line." "With the recent publication of clinical data demonstrating the clinical value of the Clarity RMS in the ICU setting, we are forging ahead with validation in additional areas like cardiology and anesthesia, in parallel with developing our pipeline of sensor-based products," said Avi Kleiman, CEO of RenalSense. "We are excited to have new investors on board who share our vision and understand the importance of digitally monitoring real-time renal function, bringing this parameter on par with the other vital signs of hospitalized patients." About BlueRed Partners BlueRed Partners  is a Singapore-based fund that focuses on investing in disruptive, early and growth-stage Israeli technology companies that offer solutions for significant market needs and trends in Asia. The management team has been based in Asia and has been investing in and advising entrepreneurs for over 20 years. Leveraging its network and investors throughout the region, BlueRed actively supports its portfolio companies to navigate local markets and scale up successfully in the region. About RenalSense RenalSense  is a privately-owned medical device company dedicated to real-time renal diagnostics. The company's first product, Clarity RMS, provides continuous, automatic monitoring of urine flow, enabling better patient care and ICU economics. RenalSense's next-generation products will provide additional real-time parameters and expanded diagnostic capabilities to further improve critical care management in the ICU and peri-operative setting.

BlueRed Partners Investments

9 Investments

BlueRed Partners has made 9 investments. Their latest investment was in RenalSense as part of their Series A on November 11, 2021.

CBI Logo

BlueRed Partners Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

11/22/2021

Series A

RenalSense

$14M

Yes

Undisclosed Investors

2

9/23/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

3/10/2021

Series C

Subscribe to see more

$99M

Subscribe to see more

10

3/10/2021

Series C

Subscribe to see more

$99M

Subscribe to see more

10

11/17/2020

Series B - II

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/22/2021

9/23/2021

3/10/2021

3/10/2021

11/17/2020

Round

Series A

Series B

Series C

Series C

Series B - II

Company

RenalSense

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$14M

$99M

$99M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Undisclosed Investors

Sources

2

10

10

10

10

BlueRed Partners Fund History

1 Fund History

BlueRed Partners has 1 fund, including BlueRed Capital Fund.

Closing Date

Fund

Fund Type

Status

Amount

Sources

6/12/2019

BlueRed Capital Fund

$75M

1

Closing Date

6/12/2019

Fund

BlueRed Capital Fund

Fund Type

Status

Amount

$75M

Sources

1

BlueRed Partners Team

1 Team Member

BlueRed Partners has 1 team member, including current Managing Partner, Daniel Harel.

Name

Work History

Title

Status

Daniel Harel

Managing Partner

Current

Name

Daniel Harel

Work History

Title

Managing Partner

Status

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.